NCT04054999

Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

Conditions

• Vasoplegic Syndrome
• Liver Transplant; Complications

Interventions

Type	Name	Description
DRUG	Hydroxocobalamin	Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
DRUG	Methylene Blue	Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes

Timeline

• Start date: 2019-11-30
• Primary completion: 2023-02-27
• Completion: 2024-02-27
• First posted: 2019-08-13
• Last updated: 2024-06-24
• Results posted: 2024-06-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study